PBM Executives Questioned On Drug Pricing Practices By Senate Finance Committee

In the wake of a proposal by the Department of HHS to remove safe harbor protections from rebates, PBMs have been resistant to full transparency, especially as it pertains to the net prices they pay for drugs and other fees they obtain in exchange for administering drug benefits.

Source: Forbes.com Healthcare News - April 15, 2019 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Source Type: news